Cargando…
Elevated plasma levels of CXCL16 in severe COVID-19 patients
Genome-wide association studies have recently identified 3p21.31, with lead variant pointing to the CXCR6 gene, as the strongest thus far reported susceptibility risk locus for severe manifestation of COVID-19. In order the determine its role, we measured plasma levels of Chemokine (C‐X‐C motif) lig...
Autores principales: | Smieszek, Sandra P., Polymeropoulos, Vasilios M., Polymeropoulos, Christos M., Przychodzen, Bartlomiej P., Birznieks, Gunther, Polymeropoulos, Mihael H. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Authors. Published by Elsevier Ltd.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8801318/ https://www.ncbi.nlm.nih.gov/pubmed/35121493 http://dx.doi.org/10.1016/j.cyto.2022.155810 |
Ejemplares similares
-
Assessing the potential correlation of polymorphisms in the IL6R with relative IL6 elevation in severely ill COVID-19 patients’
por: Smieszek, Sandra P., et al.
Publicado: (2021) -
Corrigendum to “Assessing the potential correlation of polymorphisms in the IL6R with relative IL6 elevation in severely ill COVID-19 patients” [Cytokine 148 (2021) 155662]
por: Smieszek, Sandra P., et al.
Publicado: (2022) -
Case report: A novel missense variant in melanopsin associates with delayed sleep phenotype: Whole genome sequencing study
por: Smieszek, Sandra P., et al.
Publicado: (2022) -
Loss-of-function mutations in IFNAR2 in COVID-19 severe infection susceptibility
por: Smieszek, Sandra P., et al.
Publicado: (2021) -
Once-daily tasimelteon (VEC-162) for jet lag following transmeridian travel: A multicenter, randomized, double-blind, placebo-controlled trial
por: Polymeropoulos, Christos M., et al.
Publicado: (2022)